ScreenerHero
VTRSViatris, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · viatris.com
16.10USD-0.87%Mkt Cap: 18.66B $P/E: —

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap18.66B $
Enterprise Value30.63B $
Revenue (TTM)14.74B $
Gross Profit5.01B $
Net Income (TTM)-3.51B $
Revenue/Share12.71 USD
Last Price16.10 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees30.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS92556V1061
Valuation
P/E (Trailing)—
P/E (Forward)6.04
PEG1.05
EV/EBITDA7.13
EV/Revenue2.08
P/S1.26
P/B1.28
EPS (TTM)-0.37
EPS (Forward)2.67
52W Range
9.43074% of range18.39
52W High18.39 USD
52W Low9.430 USD
Profitability
Gross Margin35.06%
Oper. Margin12.55%
EBITDA Margin29.13%
Profit Margin-24.58%
ROE-23.89%
ROA-9.45%
Growth
Revenue Growth4.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF2.32B $
CapEx (TTM)465.10M $
FCF Margin18.17%
FCF Yield14.35%
Net Debt12.11B $
Net Debt/EBITDA2.82
Balance Sheet
Debt/Equity1.00
Current Ratio1.58
Quick Ratio0.82
Book Value/Sh12.59 USD
Cash/Share1.315 USD
Dividends
Fwd Div Rate0.4800 USD
Trail. Div Rate0.4800 USD
Div. Yield2.96%
5Y Avg Yield4.08%
Payout Ratio960.00%
Ex-Div DateAug 21, 2026
Pay DateSep 16, 2026
Splits
Last Split3:2
Split DateOct 9, 2003
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.50 USD
Upside (mean)+14.9%
Target Range12.00 USD – 23.00 USD
$12.00+14.9% to mean$23.00
# Analysts8
Ownership
Shares Out.1.15B
Float1.14B
Insiders0.32%
Institutions93.28%
Short Interest
Short Ratio4.8d
Short % Float3.97%
Short % Out.3.95%
Shares Short45.69M
Short (prev mo.)48.02M
Technical
SMA 5016.59 (-2.9%)
SMA 20014.39 (+11.9%)
Beta0.89
S&P 52W Chg18.16%
Avg Vol (30d)9.42M
Avg Vol (10d)10.49M
Technical Indicators
RSI (14)41.7
MACD-0.1756
MACD Signal-0.0286
MACD Hist.-0.1470
BB Upper18.38 USD
BB Middle16.96 USD
BB Lower15.55 USD
BB Width16.65%
ATR (14)0.4932 USD
Vol Ratio (20d)0.56x